This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
DarioHealth Corp. Publishes Two New Peer-Reviewed Studies Demonstrating Impact of Digital Behavioral Health CI
Two National Employers Select DarioHealth Corp.'S Integrated Chronic Condition Solution to Improve Employee Health CI
Transcript : DarioHealth Corp., 2023 Earnings Call, Mar 28, 2024
DarioHealth Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
North American Morning Briefing : Stocks Set for -2- DJ
North American Morning Briefing : Investors -2- DJ
DarioHealth Corp. Announces Two New Clinical Studies Presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes 2024 CI
Transcript : DarioHealth Corp., Twill, Inc. - M&A Call
DarioHealth Corp. Appoints Tomer Ben-Kiki as Chief Operating Officer CI
DarioHealth Corp. announced that it has received $22.422 million in funding CI
DarioHealth Corp. acquired Twill, Inc. for $34.4 million. CI
DarioHealth Corp. announced that it expects to receive $22.422 million in funding CI
DarioHealth to Provide Diabetes, Weight-Control Services for Food Services Union Members MT
Regional Union Selects DarioHealth Corp.'s Cardiometabolic Solution for Diabetes, Hypertension, Weight Management and GLP-1 Support CI
National Employer Selects Dariohealth Corp. Cardiometabolic and GLP-1 Solutions to Improve Employee Health CI
DarioHealth Corp. Contracts with New Employer for Cardiometabolic Solution CI
Transcript : DarioHealth Corp., Q3 2023 Earnings Call, Nov 02, 2023
Earnings Flash (DRIO) DARIOHEALTH Posts Q3 Revenue $3.5M, vs. Street Est of $5.4M MT
DarioHealth Corp. Provides Revenue Guidance for the Year 2024 CI
DarioHealth Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
DarioHealth Launches New Blood Sugar Meter for Apple iPhone 15 Users MT
Transcript : DarioHealth Corp. - Analyst/Investor Day
DarioHealth Says Digital Health Solution Cut Hospital Readmissions by 36% for Users With Type 2 Diabetes MT
DarioHealth Corp. Signs National Preferred Partner Agreement with a Top Five National Employee Benefits Consulting Firm CI
DarioHealth Corp. Partners with PlanSource to Offer Employers Easy Access to Proven Digital Health Solutions CI
Chart DarioHealth Corp.
More charts
DarioHealth Corp. is a global digital therapeutics (DTx) company. The Company operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and highly engaging digital therapeutic interventions. Its platform and suite of solutions delivers personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Its products include Dario Blood Pressure Monitoring System and Dario Blood Glucose Monitoring Starter Kit. Dario Blood Glucose Monitoring Starter Kit is a pocket-sized smartphone glucometer that manages diabetes in one ultra-compact device. Dario Blood Pressure Monitoring System is a blood pressure monitoring system used to measure blood pressure, which allows to store all its user readings in the Dario App. Its Dario mobile app is a complete, cloud-based solution for personal chronic condition management.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.15 USD
Average target price
5.667 USD
Spread / Average Target
+392.75%
Consensus
  1. Stock Market
  2. Equities
  3. DRIO Stock
  4. News DarioHealth Corp.
  5. DarioHealth : US National Health Plan Collaborate on Digital Behavioral Health Platform